Keiko Yanagihara^1,*, Masato Yoshida², Kensaku Awaji², Tamami Yamakawa¹, Sena Kato¹, Miki Tamura¹, Koji Nagata³

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891 - 30 December 2025

Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >

Sanggu Kim¹, Seongmo Yang¹, Soochong Kim^1,2,*

BIOCELL, Vol.49, No.12, pp. 2335-2364, 2025, DOI:10.32604/biocell.2025.072418 - 24 December 2025

Abstract Regenerative medicine has attracted increasing attention across diverse organs, including the skin, musculoskeletal tissues, eye, and nervous system, where structural repair is limited. Among these, skin wound care is particularly urgent and challenging because diabetic ulcers, pressure injuries, and severe burns often resist standard dressings, debridement, and revascularization, resulting in infection, amputation, and high costs. Platelet-rich plasma (PRP) has gained value because platelets release coordinated growth factors and cytokines (e.g., platelet-derived growth factor, transforming growth factor-β, vascular endothelial growth factor, epidermal growth factor, fibroblast growth factor, and insulin-like growth factor-1) that modulate hemostasis, inflammation, angiogenesis,… More >

Huiping Qiu¹, Shaofang Huang^2,*, Xin Xiong¹, Li Zhang¹

BIOCELL, Vol.49, No.12, pp. 2415-2432, 2025, DOI:10.32604/biocell.2025.070402 - 24 December 2025

Abstract Background: Pulmonary fibrosis is an irreversible lung disorder that currently has a limited number of effective therapeutic strategies. Taraxasterol (TAR), a bioactive triterpenoid isolated from plants used in traditional Chinese medicine (TCM), possesses anti-inflammatory and antioxidant activities. However, its precise role in pulmonary fibrosis remains incompletely defined. This study aimed to elucidate whether TAR alleviates pulmonary fibrosis by modulating Protein Phosphatase 2 Scaffold Subunit Abeta (PPP2R1B) expression. Methods: A bleomycin-induced murine model of pulmonary fibrosis and a transforming growth factor-β1 (TGF-β1) stimulated mouse lung fibroblast cell line (MLg) were established. To evaluate the effects of… More >

Yuri A. Piven¹, Danila V. Sorokin², Nastassia A. Varabyeva¹, Alexandra L. Mikhaylova², Fedor B. Bogdanov², Elena V. Shafranovskaya¹, Raman M. Puzanau³, Fedor A. Lakhvich¹, Alexander M. Scherbakov^2,4,*

Oncology Research, Vol.33, No.12, pp. 4049-4072, 2025, DOI:10.32604/or.2025.067832 - 27 November 2025

Abstract Background: The most aggressive forms of breast cancer are characterized by independence from steroid hormones but a strong dependence on growth factors. In such cancer cells, oncogenic receptors, including human epidermal growth factor receptor 2 (HER2), are activated, and their targeted inhibition represents an attractive therapeutic strategy. The study aimed to develop small-molecule potential dual heat shock protein 90 (HSP90)-HER2 inhibitors and evaluate them as anticancer agents in HER2-positive cells. Methods: The research project involved obtaining a series of compounds with potential dual inhibitory activity against HSP90 and HER2 by targeted organic synthesis, which was… More > Graphic Abstract

Tian-Tian Li^1,2,3,#, Ming-Yao Meng^1,2,4,#, Zheng Yu⁵, Yang-Fan Guo^1,2,4, Yi-Yi Zhao^1,2,4, Hui Gao^1,2,4, Li-Li Yang^1,2,3, Li-Rong Yang^1,2,3, Meng-Yuan Chu^1,2,3, Shan He^1,2,4, Yuan Liu^1,2,4, Xiao-Dan Wang^1,2,4, Wen-Ju Wang^1,2,4, Zong-Liu Hou^1,2,4, Li-Wei Liao^1,2,4,*, Lin Li^1,2,4,*

Oncology Research, Vol.33, No.11, pp. 3447-3467, 2025, DOI:10.32604/or.2025.065394 - 22 October 2025

Abstract Background: Chimeric antigen receptor T (CAR-T) cell therapies have demonstrated significant clinical efficacy in hematological malignancies. However, their application to solid tumors remains substantially limited by multiple challenges, including the risk of off-target effects. Hence, optimizing CAR-T cells for stronger antigen binding is essential. Methods: In this study, we employed a classical anti-human endothelial growth factor receptor 2 (HER2) single-chain variable fragment (scFv) derived from trastuzumab, alongside an anti-HER2-13 scFv identified from a combinatorial cellular CAR library, for the construction of a third-generation CAR-T cell. Meanwhile, the phenotypes and both in vitro and in vivo functions of… More > Graphic Abstract

Chong Wang^*

The International Conference on Computational & Experimental Engineering and Sciences, Vol.33, No.1, pp. 1-1, 2025, DOI:10.32604/icces.2025.012164

Abstract Please Creating mechanically robust tissue engineering scaffolds capable of delivering growth factors and stem cells in situ for hard tissue repair remains a significant challenge. Inspired by the spiral structure of ice cream, our group developed an advanced 3D printing technique known as cryogenic 3D printing to fabricate polyester-based scaffolds with embedded growth factors. This method utilizes water-in-oil (w/o) polyester emulsions containing growth factors as the printing ink, which is patterned onto a cryogenic substrate. The resulting scaffolds feature a hierarchically porous structure, allowing mesenchymal stem cells (MSCs) to easily attach and proliferate. Additionally, the… More >

Eleni Kokkotou^*, Andriani Charpidou, Nikolaos Syrigos

Oncology Research, Vol.33, No.10, pp. 2657-2672, 2025, DOI:10.32604/or.2025.066228 - 26 September 2025

Abstract Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) serve an essential role in tumor angiogenesis and have emerged as potential therapeutic targets in lung cancer. This review explores the significance of serum VEGF levels as a predictive biomarker in non-small cell lung cancer (NSCLC). The VEGF family, consisting of VEGFA, VEGFB, VEGFC, VEGFD, and placenta growth factor (PlGF), engages with specific receptors, including tyrosine kinase receptors (VEGFR-1, VEGFR-2, and VEGFR-3) and neuropilin receptors (NRP-1 and NRP-2), to promote angiogenesis and lymphangiogenesis. VEGF-A, the primary component of the VEGF family, binds to VEGFR-2 to stimulate… More >

Wenjing Liao^1,#, Liaodi Wang^2,#, Zhen Huang¹, Ziyu Zou¹, Yimin Liu¹, Haoyue Liu¹, Zhaoning Duan¹, Liangdan Tang^1,*

Oncology Research, Vol.33, No.10, pp. 3041-3064, 2025, DOI:10.32604/or.2025.065451 - 26 September 2025

Abstract Objectives: Ovarian cancer (OC) is a highly heterogeneous disease characterized by high metastatic potential and frequent recurrence. 3β-hydroxysterol Δ24-reductase (DHCR24) is closely associated with the progression of various malignant tumors, but its role in OC remains unexplored. This study is the first to systematically investigate the function of DHCR24 in OC and elucidate its mechanism in promoting OC progression, providing novel theoretical insights for targeted therapy. Methods: The expression of DHCR24 was evaluated in tissues using bioinformatics and clinical data; the impact of DHCR24 on the malignant behavior of OC was assessed through in vivo and in… More >

Prin Sungwan¹, Jutatip Panaampon^1,2, Ratchaneewan Sumankan^1,3, Genki Aoki¹, Seiji Okada^1,*

Oncology Research, Vol.33, No.9, pp. 2279-2307, 2025, DOI:10.32604/or.2025.065319 - 28 August 2025

Abstract Cholangiocarcinoma (CCA) is a fatal bile duct malignancy. CCA is intrinsically resistant to standard chemotherapy, responds poorly to it, and has a poor prognosis. Effective treatments for cholangiocarcinoma remain elusive, and a breakthrough in CCA treatment is still awaited. The human epidermal growth factor receptor 2 (HER2) plays an oncogenic role by promoting an aggressive cancer phenotype through multiple pathways. While HER2 has shown increasing potential as an effective target for breast and gastric cancers over the last decade, this has not been the case for CCA. This review explores the possibility of targeting HER2 More > Graphic Abstract

Xi Qin^1,#, Yulan Liu^1,#, Lin Zhu², Yunyan Mo¹, Jing Zhang³, Zhuchun Jiang⁴, Dongning Huang⁵, Xinrong Hu⁶, Jingzhang Li⁷, Quanfang Chen⁸, Feng Xue^1,*

Oncology Research, Vol.33, No.9, pp. 2451-2462, 2025, DOI:10.32604/or.2025.064119 - 28 August 2025

Abstract Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events… More >